Treatment of rheumatoid arthritis with baricitinib or upadacitinib is associated with reduced scaffold protein NEDD9 levels in CD4+ T cells

Treatment of rheumatoid arthritis with baricitinib or upadacitinib is associated with reduced scaffold protein NEDD9 levels in CD4+ T cells

Abstract The JAK/STAT pathway plays a crucial role in the pathogenesis of rheumatoid arthritis (RA) and JAK inhibitors have emerged as a new group of effective drugs for RA treatment. Recently, high STAT3 levels have been associated with the upregulation of the scaffold protein NEDD9, which is a reg...

Full description

Bibliographic Details
Main Authors: Viktoria Golumba‐Nagy, Shuaifeng Yan, Eva Steinbach‐Knödgen, Jan Thiele, Ruth L. Esser, Thomas H. Haak, Anastasia Nikiforov, Anja Meyer, Tamina Seeger‐Nukpezah, David M. Kofler
Format: Article
Language:English
Published: Wiley 2023-10-01
Series:Physiological Reports
Subjects:
baricitinib
CD4+ T cells
NEDD9
rheumatoid arthritis
tofacitinib
upadacitinib
Online Access:https://doi.org/10.14814/phy2.15829

Similar Items

Similar Items